# Bifidobacterium longum BB536 DSM 20219

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-longum-bb536-dsm-20219
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** BB536, B. longum BB536, Bifidobacterium longum strain BB536, DSM 20219, B. longum DSM 20219

## Overview

Bifidobacterium longum BB536 (DSM 20219) is a clinically studied [probiotic](/ingredients/condition/gut-health) strain that modulates gut microbiota composition and immune signaling through production of short-chain fatty acids and interaction with intestinal toll-like receptors. It demonstrates documented benefits for constipation relief, ulcerative colitis remission, and restoration of beneficial Bifidobacterium and Lactobacillus populations in the colon.

## Health Benefits

• Improves bowel movement frequency in constipated adults (moderate evidence from double-blind crossover trial, n=24, PMC9636538)
• Supports ulcerative colitis remission with 63% achieving remission vs 52% placebo (moderate evidence from multicenter RCT, PMID: 26418574)
• Increases beneficial gut bacteria ratio (bifidobacteria/Enterobacteriaceae) in infants (preliminary evidence from infant trial, PMC10012958)
• Shows trend toward improved immune markers (serum IgA) in elderly (preliminary evidence from RCT, n=45, PMID: 23192454)
• May reduce visceral and total body fat when combined with B. breve (preliminary evidence from RCT, PMID: 38542727)

## Mechanism of Action

B. longum BB536 ferments dietary fibers into short-chain fatty acids (SCFAs), primarily acetate and butyrate, which fuel colonocytes and lower luminal pH to inhibit pathogenic bacteria. The strain modulates mucosal [immunity](/ingredients/condition/immune-support) by signaling through Toll-like receptor 2 (TLR2) and TLR4 on intestinal epithelial and dendritic cells, promoting regulatory T-cell differentiation and reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6. Additionally, BB536 produces bacteriocin-like inhibitory substances and competes for epithelial adhesion sites, reinforcing the intestinal barrier and reducing gut permeability.

## Clinical Summary

A double-blind crossover RCT (n=24, PMC9636538) demonstrated that BB536 supplementation significantly improved bowel movement frequency in constipated adults compared to placebo. A multicenter RCT (PMID: 26418574) found that 63% of ulcerative colitis patients achieved remission with BB536 versus 52% in the placebo group, suggesting moderate benefit as adjunct therapy. Human trials also document measurable increases in fecal Bifidobacterium and Lactobacillus counts following supplementation, indicating favorable microbiota modulation. Overall evidence is moderate in strength, derived primarily from small-to-medium RCTs; larger confirmatory trials are needed for several indications.

## Nutritional Profile

Bifidobacterium longum BB536 (DSM 20219) is a non-caloric, non-macronutrient ingredient delivered as viable bacterial cells. Typical commercial preparations contain 1–10 billion CFU (colony-forming units) per serving dose, with exact CFU varying by product format. The ingredient itself contributes negligible protein (~0.1–0.5 mg/serving from bacterial cell mass), no dietary fat, and no digestible carbohydrates. Bioactive compounds intrinsic to this strain include: (1) Exopolysaccharides (EPS) produced by BB536, which modulate immune signaling via Toll-like receptor pathways and contribute to mucosal adhesion; (2) Short-chain fatty acid (SCFA) precursor activity — BB536 ferments dietary fibers to produce acetate and lactate as primary metabolic end-products, with acetate output estimated at 1–5 mmol per 10^9 CFU in colonic conditions; (3) Bacteriocin-like inhibitory substances (BLIS) that suppress pathogenic Enterobacteriaceae growth; (4) Cell wall components including lipoteichoic acids and peptidoglycans that interact with host pattern recognition receptors. The strain does not synthesize measurable quantities of B vitamins under standard gut colonization conditions, unlike some other Bifidobacterium species. Bioavailability is defined by colonization efficiency: BB536 demonstrates moderate gastric acid and bile salt tolerance, with approximately 40–60% of ingested cells surviving transit to the colon based on fecal recovery studies. Viability is maintained in freeze-dried powder form at moisture content below 5% and storage temperatures at or below 25°C.

## Dosage & Preparation

Clinically studied doses range from 5×10¹⁰ CFU/day in powder form for elderly constipation to acid-resistant capsules for adult constipation. Most trials use once-daily administration for 2-12 weeks. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

B. longum BB536 is generally recognized as safe (GRAS) and well-tolerated in healthy adults, with adverse effects in clinical trials limited to transient mild bloating or flatulence during the initial days of supplementation. Immunocompromised individuals, including those on high-dose corticosteroids, biologics, or post-organ transplant immunosuppressants, should use live [probiotic](/ingredients/condition/gut-health) strains cautiously due to a theoretical risk of bacteremia. Concurrent use with broad-spectrum antibiotics such as fluoroquinolones or amoxicillin-clavulanate may significantly reduce viable bacterial counts and diminish efficacy; separating doses by at least 2 hours is recommended. Pregnancy and lactation safety data are limited but no significant adverse events have been reported in available studies; consultation with a healthcare provider is advised.

## Scientific Research

Clinical trials include double-blind RCTs in elderly tube-fed patients (n=45, PMID: 23192454), constipated adults (n=24, PMC9636538), ulcerative colitis patients (PMID: 26418574), and elderly with chronic constipation (n=80, PMID: 36216361). Studies consistently show increased fecal bifidobacteria counts and improvements in [digestive health](/ingredients/condition/gut-health), though primary endpoints sometimes miss statistical significance.

## Historical & Cultural Context

No historical or traditional medicine use is documented in the research. BB536 is a modern, commercially developed clinical [probiotic](/ingredients/condition/gut-health) strain without ties to traditional healing systems.

## Synergistic Combinations

Bifidobacterium breve MCC1274, [Prebiotic](/ingredients/condition/gut-health)s (FOS/GOS), Vitamin D, Zinc, Lactobacillus acidophilus

## Frequently Asked Questions

### What is the recommended dosage of Bifidobacterium longum BB536?

Clinical trials have used doses ranging from 1 billion to 10 billion CFU (colony-forming units) per day, with most gastrointestinal studies using approximately 5 billion CFU daily taken with or before meals. The optimal dose may vary by indication; ulcerative colitis RCTs typically used higher doses over 8–12 weeks. Always follow label guidance or clinician recommendations, as CFU viability depends on storage conditions.

### How long does Bifidobacterium longum BB536 take to work for constipation?

In the double-blind crossover trial (PMC9636538, n=24), significant improvements in bowel movement frequency were observed within 2–4 weeks of daily supplementation at approximately 5 billion CFU. Colonization and SCFA-driven motility effects typically require at least 1–2 weeks to manifest measurably. Benefits may diminish after discontinuation, suggesting continued use is necessary to maintain effects.

### Can Bifidobacterium longum BB536 help with ulcerative colitis?

Yes, a multicenter RCT (PMID: 26418574) found that BB536 supplementation achieved clinical remission in 63% of ulcerative colitis patients compared to 52% in the placebo group when used alongside standard mesalazine therapy. The mechanism involves reduction of mucosal TNF-α and IL-6 signaling and reinforcement of the intestinal epithelial barrier. It is considered an adjunct rather than a replacement for conventional UC medications.

### Is Bifidobacterium longum BB536 the same as regular Bifidobacterium longum?

No, BB536 (DSM 20219) is a specific proprietary strain of Bifidobacterium longum with a distinct genetic profile and documented clinical evidence; not all B. longum strains share the same properties or efficacy data. Probiotic benefits are strain-specific, meaning research on BB536 cannot be extrapolated to other B. longum strains. When purchasing supplements, verify the exact strain designation on the label.

### Does Bifidobacterium longum BB536 survive stomach acid?

BB536 has demonstrated acid and bile tolerance in in vitro studies, with meaningful survival rates through gastric pH as low as 2.0 and exposure to 0.3% bile salts. This acid tolerance is partly attributed to its production of proton-extruding ATPases and protective exopolysaccharide layers. Enteric-coated or microencapsulated formulations can further improve viable delivery to the colon, and taking the supplement with food buffers gastric acidity to enhance survival.

### Is Bifidobacterium longum BB536 safe for infants and children?

Bifidobacterium longum BB536 has been studied in infant populations and shown to increase beneficial gut bacteria ratios, suggesting safety in this age group. However, dosing for infants differs significantly from adults, and parents should consult a pediatrician before giving any probiotic supplement to children under one year old. Clinical evidence supports its use in older infants and children, particularly those with digestive concerns, but individual health status should guide supplementation decisions.

### What is the clinical evidence quality for Bifidobacterium longum BB536?

Bifidobacterium longum BB536 is supported by moderate-quality evidence from double-blind, placebo-controlled trials and multicenter randomized controlled trials, including studies on constipation relief and ulcerative colitis remission. A key multicenter RCT showed 63% remission rates in ulcerative colitis patients versus 52% with placebo, demonstrating clinically meaningful efficacy. While the evidence base is stronger than many probiotics, more large-scale studies would further establish optimal use cases and long-term safety profiles.

### Can Bifidobacterium longum BB536 interact with antibiotics or other medications?

Bifidobacterium longum BB536, like other probiotics, may be reduced or killed by broad-spectrum antibiotics, so timing separation (2+ hours apart) is typically recommended when taking both. There are no well-documented direct pharmacological interactions between this specific strain and common medications, though individuals on immunosuppressants should consult their healthcare provider. Always inform your doctor or pharmacist about probiotic supplementation if you are on prescription medications, especially those affecting gut flora or immune function.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*